NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

LIC Posts Strong Q4FY26 Performance, Exceeds Estimates

Emkay Global Financial's research report on Life Insurance Corporation (LIC) highlights a robust Q4FY26 performance, with the company delivering a VNB (Value of New Business) margin of 25.7%, a 6.9 percentage point year-over-year (YoY) increase. This surpasses Emkay Global Financial's estimate of 20.5%. Additionally, APE (Annual Premium Equivalent) stood at Rs229.5 billion, a 21.8% YoY increase, exceeding the estimated Rs212.8 billion.

The strong VNB margin during the quarter was driven by robust growth in the non-par segment and favorable movement in the yield curve. The Board declared a final dividend of Rs10 per share, with a pre-bonus dividend of Rs20 per share. Furthermore, the corporation remains conservative in maintaining solvency capital, considering the implementation of 'Risk Based Solvency' which could impact solvency capital after the transition.

Outlook and Recommendations

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

To incorporate the Q4 developments, Emkay Global Financial has increased its APE estimates by 4-5% and raised VNB margin estimates by 200-240 basis points. This results in a ~15-16% increase in VNB over FY27-28E. The research firm maintains a BUY rating on LIC and increases its March 2027 estimated target price (TP) by 10% to Rs1,100, implying a FY28E P/EV of 0.7x.

Product SegmentQ4FY26 ActualQ4FY26 EstimateYoY Change
VNB Margin25.7%20.5%+6.9ppt
APERs229.5 billionRs212.8 billion+21.8%

Investor Takeaway

Investors should consider buying LIC due to its strong Q4FY26 performance and potential for growth in VNB.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.